Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men

Abdominal visceral adipose tissue (AT) accumulation is associated with an atherogenic metabolic profile that includes increased plasma triglyceride (TG), low HDL cholesterol levels, and an insulin-resistant hyperinsulinemic state. Whereas the apolipoprotein (apo) C-III C3238G gene variant, often ref...

Full description

Bibliographic Details
Main Authors: Charles Couillard, Marie-Claude Vohl, James C. Engert, Isabelle Lemieux, Alain Houde, Natalie Alméras, Denis Prud’homme, André Nadeau, Jean-Pierre Després, Jean Bergeron
Format: Article
Language:English
Published: Elsevier 2003-05-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520311445
id doaj-2aa001d8c6ff4b42904d7adcb9f50616
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Charles Couillard
Marie-Claude Vohl
James C. Engert
Isabelle Lemieux
Alain Houde
Natalie Alméras
Denis Prud’homme
André Nadeau
Jean-Pierre Després
Jean Bergeron
spellingShingle Charles Couillard
Marie-Claude Vohl
James C. Engert
Isabelle Lemieux
Alain Houde
Natalie Alméras
Denis Prud’homme
André Nadeau
Jean-Pierre Després
Jean Bergeron
Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
Journal of Lipid Research
oral glucose tolerance test
high density lipoprotein
very low density lipoprotein
triglycerides
author_facet Charles Couillard
Marie-Claude Vohl
James C. Engert
Isabelle Lemieux
Alain Houde
Natalie Alméras
Denis Prud’homme
André Nadeau
Jean-Pierre Després
Jean Bergeron
author_sort Charles Couillard
title Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
title_short Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
title_full Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
title_fullStr Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
title_full_unstemmed Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
title_sort effect of apoc-iii gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2003-05-01
description Abdominal visceral adipose tissue (AT) accumulation is associated with an atherogenic metabolic profile that includes increased plasma triglyceride (TG), low HDL cholesterol levels, and an insulin-resistant hyperinsulinemic state. Whereas the apolipoprotein (apo) C-III C3238G gene variant, often referred to as the SstI polymorphism, has been related to variations in plasma TG concentrations, another variation within the insulin responsive element (C-482T) of the apoC-III gene has been associated with greater glucose and insulin responses to an oral glucose tolerance test (OGTT); however, these results were obtained in nonobese individuals. We therefore investigated the effects of three apoC-III gene polymorphisms, namely SstI, C-482T, and T-455C, on fasting plasma lipoprotein-lipid levels and response to a 75 g OGTT in a sample of 122 viscerally obese men (abdominal visceral AT area ≥130 cm2). Among the three gene variants that were examined, the SstI variation was the only one found to be associated with hypertriglyceridemia. Indeed, S1/S2 heterozygotes (n = 24) were characterized by increased fasting plasma TG concentrations compared with S1/S1 homozygotes (n = 98) (mean ± SD: 3.03 ± 1.58 vs. 2.34 ± 0.95 mmol/l respectively, P < 0.05). The higher TG concentrations in S1/S2 were associated with the presence of smaller, denser LDL particles compared with S1/S1 subjects (LDL peak particle diameter: 24.8 ± 0.5 nm vs. 25.1 ± 0.5 nm respectively, P < 0.05). Furthermore, there was no association between the response to the OGTT and any of the apoC-III gene variants (SstI, T-455C, or C-482T) examined.Results of the present study support the notion of a hypertriglyceridemic effect associated with the apoC-III SstI polymorphism that could modulate the magnitude of the dyslipidemic state in abdominally obese patients.
topic oral glucose tolerance test
high density lipoprotein
very low density lipoprotein
triglycerides
url http://www.sciencedirect.com/science/article/pii/S0022227520311445
work_keys_str_mv AT charlescouillard effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT marieclaudevohl effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT jamescengert effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT isabellelemieux effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT alainhoude effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT nataliealmeras effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT denisprudhomme effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT andrenadeau effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT jeanpierredespres effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
AT jeanbergeron effectofapociiigenepolymorphismsonthelipoproteinlipidprofileofviscerallyobesemen
_version_ 1721506994517442560
spelling doaj-2aa001d8c6ff4b42904d7adcb9f506162021-04-27T04:39:01ZengElsevierJournal of Lipid Research0022-22752003-05-01445986993Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese menCharles Couillard0Marie-Claude Vohl1James C. Engert2Isabelle Lemieux3Alain Houde4Natalie Alméras5Denis Prud’homme6André Nadeau7Jean-Pierre Després8Jean Bergeron9Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Department of Food Sciences and Nutrition, Laval University, Sainte-Foy, Québec, Canada, G1K 7P4; Québec Heart Institute, Sainte-Foy, Québec, Canada G1V 4G5; Lipid Research Center, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Diabetes Research Unit, Laval University Medical Research Center, CHUL Pavilion, Sainte-Foy, Québec, Canada G1V 4G2; Montréal Genome Center, McGill University Health Center Research Institute, Montréal, Québec, Canada, H3G 1A4; School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada, K1N 6N5Abdominal visceral adipose tissue (AT) accumulation is associated with an atherogenic metabolic profile that includes increased plasma triglyceride (TG), low HDL cholesterol levels, and an insulin-resistant hyperinsulinemic state. Whereas the apolipoprotein (apo) C-III C3238G gene variant, often referred to as the SstI polymorphism, has been related to variations in plasma TG concentrations, another variation within the insulin responsive element (C-482T) of the apoC-III gene has been associated with greater glucose and insulin responses to an oral glucose tolerance test (OGTT); however, these results were obtained in nonobese individuals. We therefore investigated the effects of three apoC-III gene polymorphisms, namely SstI, C-482T, and T-455C, on fasting plasma lipoprotein-lipid levels and response to a 75 g OGTT in a sample of 122 viscerally obese men (abdominal visceral AT area ≥130 cm2). Among the three gene variants that were examined, the SstI variation was the only one found to be associated with hypertriglyceridemia. Indeed, S1/S2 heterozygotes (n = 24) were characterized by increased fasting plasma TG concentrations compared with S1/S1 homozygotes (n = 98) (mean ± SD: 3.03 ± 1.58 vs. 2.34 ± 0.95 mmol/l respectively, P < 0.05). The higher TG concentrations in S1/S2 were associated with the presence of smaller, denser LDL particles compared with S1/S1 subjects (LDL peak particle diameter: 24.8 ± 0.5 nm vs. 25.1 ± 0.5 nm respectively, P < 0.05). Furthermore, there was no association between the response to the OGTT and any of the apoC-III gene variants (SstI, T-455C, or C-482T) examined.Results of the present study support the notion of a hypertriglyceridemic effect associated with the apoC-III SstI polymorphism that could modulate the magnitude of the dyslipidemic state in abdominally obese patients.http://www.sciencedirect.com/science/article/pii/S0022227520311445oral glucose tolerance testhigh density lipoproteinvery low density lipoproteintriglycerides